Ideas

Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA DSCAMAS1 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 6/Februay/2019, 11.11 pm
Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA DSCAMAS1 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 6/Februay/2019, 11.11 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center for the Biology of…

read more

Ribonucleic acid-based therapy for cardiomyocyte proliferation and heart regeneration: LncRNA PCGEM decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 6/February/2019, 11.00 pm
Ribonucleic acid-based therapy for cardiomyocyte proliferation and heart regeneration: LncRNA PCGEM decreases tumor suppressor MiR-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 6/February/2019, 11.00 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and…

read more

Ribonucleic acid-based therapy for diabetes: LncRNA MYU increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 6/February/2019, 10.51 am
Ribonucleic acid-based therapy for diabetes: LncRNA MYU increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 6/February/2019, 10.51 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:   A study from the Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA shows that “The Lin28/let-7 axis regulates glucose metabolism.” This study…

read more

Ribonucleic acid-based therapy for TIIDM and obesity-associated metabolic deficits: LncRNA  H19 increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 5/February/2019, 10.33 pm
Ribonucleic acid-based therapy for TIIDM and obesity-associated metabolic deficits: LncRNA  H19 increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 5/February/2019, 10.33 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite by…

read more

Probiotic-based therapy for body weight control, energy homeostasis, and TIIDM: Probiotic Clostridium butyricum MIYAIRI 588 (CBM588)  increases REV-ERB and its downstream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 5/February/2019, 10.17 pm
Probiotic-based therapy for body weight control, energy homeostasis, and TIIDM: Probiotic Clostridium butyricum MIYAIRI 588 (CBM588)  increases REV-ERB and its downstream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 5/February/2019, 10.17 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic…

read more

Ribonucleic acid-based therapy for cardiac hypertrophy and fibrosis: lncRNA PCGEM  decreases MiR-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 5/January/2019, 10.06 pm
Ribonucleic acid-based therapy for cardiac hypertrophy and fibrosis: lncRNA PCGEM  decreases MiR-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 5/January/2019, 10.06 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from the Institute of Pharmacology and Toxicology, Technical University Munich (TUM), 80802, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich…

read more
Start Typing